Cargando…
Proof-of-principle studies on a strategy to enhance nucleotide imbalance specifically in cancer cells
Highly specific and potent inhibitors of dihydroorotate dehydrogenase (DHODH), an essential enzyme of the de novo pyrimidine ribonucleotide synthesis pathway, are in clinical trials for autoimmune diseases, viral infections and cancer. However, because DHODH inhibitors (DHODHi) are immunosuppressant...
Autores principales: | Alkasalias, Twana, Zhang, Juan, Madapura, Harsha, Dalarun, Basile, Reina, Oscar Bedoya, Lewensohn, Rolf, Viktorsson, Kristina, Salihi, Abbas, Darekar, Suhas, Laín, Sonia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691752/ https://www.ncbi.nlm.nih.gov/pubmed/36424385 http://dx.doi.org/10.1038/s41420-022-01254-4 |
Ejemplares similares
-
Correction: Proof-of-principle studies on a strategy to enhance nucleotide imbalance specifically in cancer cells
por: Alkasalias, Twana, et al.
Publicado: (2022) -
Gasotransmitters in the tumor microenvironment: Impacts on cancer chemotherapy
por: Salihi, Abbas, et al.
Publicado: (2022) -
Fibroblasts in the Tumor Microenvironment: Shield or Spear?
por: Alkasalias, Twana, et al.
Publicado: (2018) -
DHODH inhibition modulates glucose metabolism and circulating GDF15, and improves metabolic balance
por: Zhang, Juan, et al.
Publicado: (2021) -
The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein
expression in SCLC patients receiving platinum-based
chemotherapy
por: Tendler, Salomon, et al.
Publicado: (2020)